决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Identifying and reprogramming softness-driven cancer stem-like cells overcomes CAR-T cell resistance in solid tumours.
实体瘤表现出显著的力学异质性,但这力学线索如何影响癌细胞对 T 细胞疗法的敏感性仍不清楚。
实体瘤具有显著的力学异质性,但这类力学信号如何影响癌细胞对 T 细胞疗法的敏感性尚不明确。本研究发现,在软基质上生长的癌细胞对CAR-T 细胞的细胞毒作用不敏感,并表现为细胞外三磷酸腺苷(ATP)升高和钙活动持续。为阐明杀伤减少的机制,我们旨在识别响应基质柔软性的细胞。研究人员构建了一种多西环素门控、钙激活的转录型力学记录器,可整合特定记录窗口内由柔软基质诱导的钙活动,并将既往信号历史转化为可持续数天的稳定荧光输出。不同于仅报告成像瞬间钙活动的实时钙指示剂,该记录器保留了可分选的转录标记,使研究人员能够根据细胞过去的力学感知活动进行选择性标记和分析。转录组分析显示,在多种癌细胞系及患者来源样本中,记录器阳性细胞均呈现干细胞样程序,包括上皮-间质转化、缺氧应答、致癌信号和干性标志物升高。为使这些耐药细胞可被靶向,研究人员将力学记录器改造为“力学重编程器”,以临床已验证的抗原 CD19 替换荧光输出,使响应柔软性的细胞可被 CD19 靶向 T 细胞识别。改造后的系统在细胞培养和动物模型中提高了对干细胞样癌细胞的清除能力,将力学生物学介导的耐药转化为治疗易感性。
Solid tumours show substantial mechanical heterogeneity, yet how such cues influence the susceptibility of cancer cells to T cell-based therapies remains unclear. Here we discover that cancer cells grown on soft matrices are less sensitive to chimeric antigen receptor T cell cytotoxicity and exhibit elevated extracellular adenosine triphosphate and sustained calcium activity. To understand the mechanisms underlying this reduced killing, we sought to identify the cells that respond to mechanical softness. We engineered a doxycycline-gated calcium-activated transcriptional mechano-recorder that integrates softness-induced calcium activity over a defined recording window and converts this prior signalling history into a stable fluorescent output that persists for days. Unlike real-time calcium indicators, which report instantaneous calcium activity only at the moment of imaging, this recorder preserves a sortable transcriptional mark, enabling selective labelling and profiling of cells according to their past mechanosensing activity. Transcriptomic analyses showed that recorder-positive cells adopt a stem-like programme, including epithelial-mesenchymal transition, hypoxia responses, oncogenic signalling and elevated stemness markers, across cancer cell lines and patient-derived samples. To render these resistant cells targetable, we rewired the mechano-recorder into a mechano-reprogrammer by replacing the fluorescent output with the clinically validated antigen CD19, enabling softness-responsive cells to be recognized by CD19-directed T cells. This rewired system improved elimination of stem-like cancer cells in culture and animal models, converting mechanobiological resistance into therapeutic vulnerability.
MEMBER ACCOUNT
登录成功会直接打开下一页。